Startup profile · funding coverage
Thyme Care funding, valuation and investors
Value-based oncology care navigation and support platform for cancer patients.
Keep track of Thyme Care
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series E
$125M+ · September 2026
Latest known valuation
>$2B
Series E · September 2026
Total disclosed equity funding
$60M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Nashville, Tennessee, USA
Investors in latest funding
Lead: Morgan Health
Other: Humana , CVS Health Ventures , AlleyCorp , Andreessen Horowitz , Frist Cressey Ventures , Foresite Capital , Town Hall Ventures , HealthQuest Capital , Concord Health Partners
Overview
Thyme Care partners with health plans, employers, and oncology providers to deliver value-based cancer care — combining a technology-enabled care team, Thyme Box platform, and virtual patient support to improve outcomes and reduce total cost. Co-founded by Robin Shah and Dr. Bobby Green, the Nashville company raised over $125 million in a Series E on September 2, 2026 led by Morgan Health at a valuation of more than $2 billion, with Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health participating. Alongside the raise, Thyme Care established Thyme Companies, a parent entity to build independent oncology businesses starting with biosimilar adoption and clinical-trial accrual.
Why Thyme Care is interesting
September 2, 2026 $125M+ Series E above a $2B valuation led by Morgan Health with Humana, CVS Health Ventures, AlleyCorp, and a16z Bio + Health — launching parent entity Thyme Companies for biosimilars and trial access.
Product & use cases
Thyme Care's Thyme Box platform and Care Team guide cancer patients through treatment — triaging symptoms, coordinating social support, and integrating with oncology practices in value-based contracts.
- Health plans managing oncology spend under risk contracts
- Community oncologists participating in value-based arrangements
- Patients needing navigation for transportation, food, and palliative support
Key facts
- Series E (Sep 2, 2026): $125M+ led by Morgan Health; valuation >$2B
- Strategics: Humana, CVS Health Ventures; VCs include AlleyCorp, a16z Bio + Health, Frist Cressey
- Launched Thyme Companies parent for biosimilars and trial accrual businesses
- Earlier: Series B Aug 2023 $60M; Series D ~$97M within prior year
Funding history (newest first)
Series E
2026-09 $125M+ Valuation: >$2B- Morgan Health (lead)
- Humana (participant)
- CVS Health Ventures (participant)
- AlleyCorp (participant)
- Andreessen Horowitz (participant)
- Frist Cressey Ventures (participant)
- Foresite Capital (participant)
- Town Hall Ventures (participant)
- HealthQuest Capital (participant)
- Concord Health Partners (participant)
Series B
2023-08 $60M- Town Hall Ventures (lead)
- Foresite Capital (lead)
- Andreessen Horowitz (participant)
- Frist Cressey Ventures (participant)
Source: https://blog.thymecare.com/press/pr-thyme-care-secures-60m-series-b
Investors in our directory
Funds linked from Thyme Care's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Oncology-specific value-based care operator — not generic care navigation — with payer accountability for cost and quality.
Oncology VBC is early versus diabetes or kidney care. Thyme Care's bet is that payers will outsource navigation and risk management as CMS models expand — and that navigation data can spawn adjacent businesses via Thyme Companies.
-
Oak Street / agilon (primary care VBC) adjacent
Value-based primary care models; different specialty.
-
Cardinal Health nav teams incumbent
Payer and PBM navigation services.
-
Academic cancer center programs incumbent
In-house navigation; less scaled technology layer.
Notable stories
- CMO Bobby Green said 'the best medicine isn't effective if a patient can't afford treatment or get a ride' — Thyme Care's thesis is removing non-clinical barriers in value-based oncology (Fierce Healthcare, 2023).
Industries
Related funding articles
Venture Capital Tracker pieces that cover Thyme Care's financing or category context.
FAQs about Thyme Care
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.